Headache surgery has become a considerable therapeutic option in headache treatment and is of rising interest in the German medical sector. This viewpoint outlines the need for reimbursement of headache surgery in the German healthcare system and demonstrates its cost-effectiveness. Using state-of-the-art patient selection algorithms, the authors found headache surgery to be cost-effective within 7.2 to 6.3 years. Of note, the approach presented is not limited to the German healthcare system.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526409 | PMC |
http://dx.doi.org/10.1016/j.jpra.2021.09.001 | DOI Listing |
Curr Pain Headache Rep
January 2025
Department of Anesthesiology, Advocate Illinois Masonic Medical Center, Chicago, IL, 60657, USA.
Purpose Of The Review: In the United States, spinal cord injuries affect approximately 18,000 individuals annually, most commonly resulting from mechanical trauma. The consequent paraplegia severely impairs motor functions, creating an urgent need for innovative therapeutic strategies that extend beyond traditional rehabilitation and pharmacotherapy. This review assesses the effectiveness of Spinal Cord Stimulation (SCS) in improving motor function in patients with spinal cord injuries, with a particular focus on paraplegia.
View Article and Find Full Text PDFClin Case Rep
February 2025
Personalized Precision Health Systems Foundation Bengaluru Karnataka India.
A 42-year-old female with left nasal blockage, facial numbness, upper palate pain, and headache was diagnosed with fungal ball sinusitis via CT scan. Refusing surgery, she opted for Ayurveda. Comprehensive treatment led to complete symptom resolution and a clear CT scan at 3 months.
View Article and Find Full Text PDFCrohns Colitis 360
January 2025
Division of Digestive Diseases and Nutrition, Department of Medicine, University of Kentucky College of Medicine, Lexington, KY, USA.
Background: Despite advancements in the therapeutic armamentarium for Crohn's disease (CD), biologic and small molecule monotherapies are associated with sub-optimal response and remission rates. Utilizing dual biologic therapy (DBT) holds the potential to increase efficacy in the treatment of refractory or partially responsive CD. Evidence pertaining to this strategy remains limited.
View Article and Find Full Text PDFHeadache
January 2025
Department of Neurological Surgery, Rutgers-New Jersey Medical School, Newark, New Jersey, USA.
A patient with persistent refractory headaches from aneurysmal subarachnoid hemorrhage was treated with monthly erenumab injections, a monoclonal antibody to the calcitonin gene-related peptide (CGRP) receptor. These injections decreased the frequency and severity of the patient's debilitating headaches from daily to once or twice per month with positive improvement in function and quality of life. To our knowledge, this is the first reported case in the literature of a patient with persistent post-subarachnoid hemorrhage headache that was successfully treated with an antibody against the CGRP receptor.
View Article and Find Full Text PDFWorld Neurosurg
January 2025
Department of Neurological Surgery, University of Louisville, Louisville, KY, USA. Electronic address:
Aneurysms of the middle cerebral artery (MCA) account for up to 40% of all unruptured intracranial aneurysms [1-3] and 14% to 20% of ruptured ones. [4-5] Giant MCA aneurysms are rare, representing 10% of cases [6], but carry an aggressive natural history, with the UCAS Japan study reporting an annual rupture rate of ∼ 17%. [7].
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!